This is the 98th instalment in a series on dementia, including the research into its causes and treatment, advice for carers and stories of hope. Dementia news is almost relentlessly grim – a steady drumbeat of rising cases and elusive cures. More bad news came in 2025, when semaglutide, the blockbuster GLP-1 drug celebrated for treating diabetes, obesity and various other conditions, failed to slow Alzheimer’s progression. The setback prompted semaglutide’s developer, Novo Nordisk, to pull the...